Effects of intravascular administration of mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord on systemic immunomodulation and neuroinflammation after traumatic brain injury (TRAUMACELL): study protocol for a multicentre randomised controlled trial
IntroductionTraumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between...
Saved in:
| Published in | BMJ open Vol. 14; no. 12; p. e091441 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
British Medical Journal Publishing Group
31.12.2024
BMJ Publishing Group LTD BMJ Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2044-6055 2044-6055 |
| DOI | 10.1136/bmjopen-2024-091441 |
Cover
| Abstract | IntroductionTraumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.Methods and analysisThe TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18–50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [18F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.Ethics and disseminationThe TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.Trial registration numberNCT06146062, first posted 24 November 2023Protocol version identifierTRAUMACELL−V.2.0_20240102 |
|---|---|
| AbstractList | Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.
The TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18-50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [
F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.
The TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.
NCT06146062, first posted 24 November 2023 PROTOCOL VERSION IDENTIFIER: TRAUMACELL-V.2.0_20240102. IntroductionTraumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.Methods and analysisThe TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18–50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [18F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.Ethics and disseminationThe TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.Trial registration numberNCT06146062, first posted 24 November 2023Protocol version identifierTRAUMACELL−V.2.0_20240102 Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.INTRODUCTIONTraumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.The TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18-50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [18F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.METHODS AND ANALYSISThe TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18-50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [18F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.The TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.ETHICS AND DISSEMINATIONThe TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.NCT06146062, first posted 24 November 2023 PROTOCOL VERSION IDENTIFIER: TRAUMACELL-V.2.0_20240102.TRIAL REGISTRATION NUMBERNCT06146062, first posted 24 November 2023 PROTOCOL VERSION IDENTIFIER: TRAUMACELL-V.2.0_20240102. Introduction Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. A growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post-traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts. We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.Methods and analysis The TRAUMACELL trial is a prospective, national multicentre, phase III, superiority, double-arm comparative randomised (1:1) double-blinded clinical trial. Among patients aged between 18–50, with a severe TBI defined by a Glasgow score less than 12 (within the first 48 hours) with brain traumatic lesion on CT Scan and needing intracranial pressure monitoring, with no other significant organ trauma (abbreviated injury scale<2) and unresponsive to verbal commands after 5 days of sedation discontinuation, 68 will be randomly allocated to receive either WJ-UC-MSC solution or placebo, with three intravenous injections 1 week apart. The primary outcome is the [18F]-DPA-714 signal intensity in corpus callosum measured by dynamic positron emission tomography (PET)-MRI at 6 months after the last injection, blinded to the randomisation arm, to evaluate the post-traumatic neuro-inflammation.Ethics and dissemination The TRAUMACELL trial has been approved by an independent ethics committee (CPP SUD EST II) and French Medicines Agency (2023-504415-33-00) for all study centres. Participant recruitment will be starting in September 2024. Results will be published in international peer-reviewed medical journals.Trial registration number NCT06146062, first posted 24 November 2023Protocol version identifier TRAUMACELL−V.2.0_20240102 |
| Author | Boutonnet, Mathieu Galanaud, Damien Degos, Vincent Sigaut, Stéphanie Habert, Marie-Odile Cras, Audrey Couffignal, Camille Gervais, Philippe Boucher-Pillet, Hélène Menasche, Philippe Tardivon, Coralie Monsel, Antoine Roquilly, Antoine Cavalier, Ines Florence, Aline-Marie Bottlaender, Michel Jacquens, Alice |
| Author_xml | – sequence: 1 givenname: Stéphanie orcidid: 0000-0002-4888-7769 surname: Sigaut fullname: Sigaut, Stéphanie email: stephanie.sigaut@aphp.fr organization: NeuroDiderot, Neuroprotection of the Developing Brain, Université Paris Cité, INSERM, Paris, Île-de-France, France – sequence: 2 givenname: Coralie surname: Tardivon fullname: Tardivon, Coralie organization: Hôpital Bichat, DMU PRISME, Biostatistics Department and Clinical Trial Units, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 3 givenname: Alice surname: Jacquens fullname: Jacquens, Alice organization: Department of Neuroanesthesiology and Neurointensive Care, Pitié Salpêtrière Hospital, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 4 givenname: Michel surname: Bottlaender fullname: Bottlaender, Michel organization: CEA, Neurospin, UNIACT, Université Paris-Saclay, Gif-sur-Yvette, Île-de-France, France – sequence: 5 givenname: Philippe surname: Gervais fullname: Gervais, Philippe organization: CEA, INSERM, CNRS, BioMaps, Service Hospitalier Frédéric Joliot, Paris-Saclay University Faculty of Science Orsay, Orsay, Île-de-France, France – sequence: 6 givenname: Marie-Odile surname: Habert fullname: Habert, Marie-Odile organization: CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, LIB, Sorbonne University, Paris, Île-de-France, France – sequence: 7 givenname: Antoine surname: Monsel fullname: Monsel, Antoine organization: UMRS_959, Immunology–Immunopathology–Immunotherapy (I3), INSERM, Paris, Île-de-France, France – sequence: 8 givenname: Antoine surname: Roquilly fullname: Roquilly, Antoine organization: Center for Research in Transplantation and Translational Immunology, UMR 1064, Université de Nantes, Nantes, Pays de la Loire, France – sequence: 9 givenname: Mathieu orcidid: 0000-0002-7334-0132 surname: Boutonnet fullname: Boutonnet, Mathieu organization: Federation of Anaesthesiology, Intensive Care Unit, Burns and Operating Theatre, Hopital d'Instruction des Armees Percy, Clamart, France – sequence: 10 givenname: Damien surname: Galanaud fullname: Galanaud, Damien organization: Hôpital de la Pitié-Salpêtrière, Neuroradiology Department, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 11 givenname: Audrey surname: Cras fullname: Cras, Audrey organization: Hôpital Saint-Louis, MEARY Center for Cell and Gene Therapy, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 12 givenname: Hélène surname: Boucher-Pillet fullname: Boucher-Pillet, Hélène organization: Hôpital Saint-Louis, MEARY Center for Cell and Gene Therapy, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 13 givenname: Aline-Marie surname: Florence fullname: Florence, Aline-Marie organization: Hôpital Bichat, DMU PRISME, Biostatistics Department and Clinical Trial Units, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 14 givenname: Ines surname: Cavalier fullname: Cavalier, Ines organization: Hôpital Bichat, DMU PRISME, Biostatistics Department and Clinical Trial Units, Assistance Publique—Hôpitaux de Paris, Paris, Île-de-France, France – sequence: 15 givenname: Philippe surname: Menasche fullname: Menasche, Philippe organization: Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, France – sequence: 16 givenname: Vincent surname: Degos fullname: Degos, Vincent organization: Anesthésie et Neuro-Réanimation chirurgicale Babinski, Assistance Publique Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Paris, France – sequence: 17 givenname: Camille orcidid: 0000-0002-5006-6249 surname: Couffignal fullname: Couffignal, Camille organization: Unité de recherche Clinique, Hôpital Bichat—Claude-Bernard, Paris, Île-de-France, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39740941$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAQDaiIltIbNyRkiUs5LPVndsMFVVWBokVIqBXHyHEmXa_8sbWTSnvjb_D3-CVMdpfSciAXW2_ee_PGmWfFXogBiuIlo28ZE-VJ45dxBWHCKZcTWjEp2ePigFMpJyVVau_efb84ynlJ8ZOqUoo_LfZFNZW0kuzg0YvzrgPTZxI7YkOf9K3OZnA6Ed16G2xGqLcxjHUPGYJZrL12BPE4ngacy6SFZG-hJR2C5PtCpz6GXz9-ZvIZy-tR2y-ADL6xzppRFVNL0DSvcw_eGmK9H0L0scXWm3Y6tCTAkKINndPe79Cuh0Qw0jAChjRJ24C5l0Nak-PLb6dXX07PzufzN-8w4NCuySrFPproSBdxIuIHhzLAOYEkbBG9zRjbRESic3jtk9XuefGk0y7D0e48LK4-nF-efZrMv368ODudTxpZ0X5SMj5tG60rSmeKgwBeiVk5A2m05m2lQJRayFJQNpMUoJu2atqWqqIV5Yxh4bC42Pq2US_rVbJep3Udta03QEzXNT6lNQ7qBngrUKjVTEkwVWNEQzsu2RRYJTuGXu-3Xquh8dBuhtTugenDSrCL-jre1oxNZaWERIfjnUOKNwPkvsbXGf-vDhCHXAumqOKCc47U1_9Ql3FIAd9qwxKYlI3jvbof6S7Ln-1DgtgSTIo5J-juKIzW45rXuzWvxzWvt2uOqpOtCot_-_5P8RuBZwgW |
| Cites_doi | 10.1002/ana.22455 10.1038/nrneurol.2017.13 10.2967/jnumed.112.118885 10.1002/stem.2538 10.1016/j.brainres.2013.08.001 10.1007/s00401-018-1944-6 10.1002/ana.26657 10.1136/bmj.c332 10.1016/j.mcn.2015.03.001 10.1002/glia.22357 10.3171/2009.9.JNS09626 10.1038/s41598-019-49428-y 10.3171/jns.2006.104.2.272 10.1093/brain/aww017 10.1016/j.accpm.2017.12.001 10.1523/JNEUROSCI.2900-11.2012 10.1186/s13054-022-03930-4 10.1186/s12974-016-0604-9 10.1002/sctm.19-0202 10.1186/s13287-021-02609-x 10.1016/j.parkreldis.2020.11.011 10.2174/157488811796575332 10.1007/s40263-016-0355-2 10.7326/0003-4819-158-3-201302050-00583 10.1016/j.eclinm.2019.100249 10.1177/0271678X17692599 10.1038/s41536-021-00182-8 10.1212/WNL.0000000000207811 10.1186/s13054-022-04287-4 10.1227/NEU.0b013e318207734c 10.3389/fneur.2017.00028 10.2174/1574888x11308020005 10.1056/NEJM199701233360422 10.3390/brainsci9100270 10.1080/14653240701883061 10.1038/jcbfm.2014.194 10.1097/PCC.0000000000000324 10.1089/neu.2015.4126 10.1186/s13287-015-0034-0 10.1016/S1474-4422(17)30118-7 10.3892/etm.2017.4423 10.1007/s00259-014-2727-5 10.1016/j.tips.2015.04.003 10.6002/ect.2012.0053 10.1016/j.tins.2016.03.002 10.1038/jcbfm.2013.133 10.1016/B978-0-12-809880-6.00023-0 10.2174/1574888X11308020005 10.1177/0271678x17692599 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2024 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. – notice: 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. 2024 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU COVID DWQXO FYUFA GHDGH GNUQQ K9- K9. KB0 M0R M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM DOA |
| DOI | 10.1136/bmjopen-2024-091441 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central BMJ Journals ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database Health & Medical Collection (Alumni) Medical Database Psychology Database (ProQuest) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition BMJ Journals ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2044-6055 |
| ExternalDocumentID | oai_doaj_org_article_be2d3090a5854ec9bc3b0f2417e194f1 PMC11749534 39740941 10_1136_bmjopen_2024_091441 bmjopen |
| Genre | Clinical Trial Protocol Journal Article |
| GrantInformation_xml | – fundername: Keep Fighting Foundation – fundername: Direction Générale de l’offre de Soins funderid: http://dx.doi.org/10.13039/501100009243 – fundername: Agence Nationale de la Recherche funderid: http://dx.doi.org/10.13039/501100001665 – fundername: ; |
| GroupedDBID | --- 4.4 53G 5VS 7RV 7X7 7~R 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKNYI BPHCQ BTFSW BTHHO CCPQU DIK DWQXO EBS FYUFA GNUQQ GROUPED_DOAJ GX1 HMCUK HYE HZ~ K9- KQ8 M0R M1P M2M M48 M~E NAPCQ O9- OK1 PGMZT PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RHI RMJ RPM UKHRP AAYXX ADRAZ BVXVI CITATION EJD H13 PHGZM CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK COVID K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-b490t-6127dbaa900852e3e293868e4caa2d95e36a346301840eef7d57d659090211463 |
| IEDL.DBID | M48 |
| ISSN | 2044-6055 |
| IngestDate | Wed Aug 27 01:29:04 EDT 2025 Thu Aug 21 18:41:20 EDT 2025 Thu Sep 04 18:21:52 EDT 2025 Fri Jul 25 22:25:13 EDT 2025 Mon Jul 21 05:39:53 EDT 2025 Tue Jul 01 03:26:03 EDT 2025 Thu Apr 24 22:49:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Brain Injuries Clinical Trial Mesenchymal Stem Cells NUCLEAR MEDICINE Neuroradiology Adult intensive & critical care |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b490t-6127dbaa900852e3e293868e4caa2d95e36a346301840eef7d57d659090211463 |
| Notes | Protocol ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. None declared. |
| ORCID | 0000-0002-5006-6249 0000-0002-7334-0132 0000-0002-4888-7769 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/bmjopen-2024-091441 |
| PMID | 39740941 |
| PQID | 3150330916 |
| PQPubID | 2040975 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_be2d3090a5854ec9bc3b0f2417e194f1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11749534 proquest_miscellaneous_3150523222 proquest_journals_3150330916 pubmed_primary_39740941 crossref_primary_10_1136_bmjopen_2024_091441 bmj_journals_10_1136_bmjopen_2024_091441 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-31 |
| PublicationDateYYYYMMDD | 2024-12-31 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationTitle | BMJ open |
| PublicationTitleAbbrev | BMJ Open |
| PublicationTitleAlternate | BMJ Open |
| PublicationYear | 2024 |
| Publisher | British Medical Journal Publishing Group BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: British Medical Journal Publishing Group – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Hill, Coleman, Menon (R2) 2016; 39 Wang, Yi, Song (R12) 2021; 12 Wang, Li, Wang (R13) 2023; 27 Gyoneva, Ransohoff (R3) 2015; 36 Yoder, Nho, Risacher (R24) 2013; 54 Cox, Baumgartner, Harting (R15) 2011; 68 Wang, Cheng, Dai (R17) 2013; 1532 Hamelin, Lagarde, Dorothée (R36) 2016; 139 Gruenbaum, Zlotnik, Gruenbaum (R1) 2016; 30 Abourbeh, Thézé, Maroy (R34) 2012; 32 Hasan, Deeb, Rahal (R28) 2017; 8 Gardner, Yaffe (R6) 2015; 66 Das, Mayilsamy, Tang (R7) 2019; 9 Chan, Tetzlaff, Altman (R21) 2013; 158 Venneti, Lopresti, Wiley (R31) 2013; 61 Brazinova, Rehorcikova, Taylor (R46) 2021; 38 Thompson, Mei, Wolfe (R11) 2020; 19 Morganti-Kossmann, Semple, Hellewell (R29) 2019; 137 Zhang, Guan, Zhang (R14) 2008; 10 Skandsen, Kvistad, Solheim (R30) 2010; 113 Monsel, Hauw-Berlemont, Mebarki (R43) 2022; 26 Cox, Hetz, Liao (R19) 2017; 35 Carvalho, Teixeira, Reis (R45) 2011; 6 Chrostek, Fellows, Guo (R9) 2019; 9 Schulz, Altman, Moher (R42) 2010; 340 Rissanen, Tuisku, Luoto (R40) 2015; 35 García-Lorenzo, Lavisse, Leroy (R41) 2018; 38 Pischiutta, Caruso, Lugo (R10) 2021; 6 Ramlackhansingh, Brooks, Greenwood (R4) 2011; 70 Israel, Ohsiek, Al-Momani (R33) 2016; 13 Simon, McGeachy, Bayır (R5) 2017; 13 Wang, Luo, Chen (R20) 2017 Hamzaoui, Garcia, Boffa (R37) 2023; 94 Cheval, Rodrigo, Taussig (R38) 2023; 101 Stocchetti, Carbonara, Citerio (R22) 2017; 16 (R47) 1997; 336 Tian, Wang, Wang (R16) 2013; 11 Peng, Sun, Sheng (R27) 2015; 6 Ikoma, Edison, Ramlackhansingh (R39) 2013; 33 Liao, Harting, Hetz (R18) 2015; 16 Batsali, Kastrinaki, Papadaki (R44) 2013; 8 Mahmood, Lu, Qu (R25) 2006; 104 Geeraerts, Velly, Abdennour (R23) 2018; 37 Wang, Yue, Kiesewetter (R35) 2014; 41 Lavisse, Goutal, Wimberley (R32) 2021; 82 Kabat, Bobkov, Kumar (R26) 2020; 9 Geeraerts (2024123108301204000_14.12.e091441.23) 2018; 37 Hasan (2024123108301204000_14.12.e091441.28) 2017; 8 2024123108301204000_14.12.e091441.39 2024123108301204000_14.12.e091441.18 Wang (2024123108301204000_14.12.e091441.13) 2023; 27 Das (2024123108301204000_14.12.e091441.7) 2019; 9 2024123108301204000_14.12.e091441.40 2024123108301204000_14.12.e091441.41 Cox (2024123108301204000_14.12.e091441.19) 2017; 35 Monsel (2024123108301204000_14.12.e091441.43) 2022; 26 Pischiutta (2024123108301204000_14.12.e091441.10) 2021; 6 2024123108301204000_14.12.e091441.24 2024123108301204000_14.12.e091441.25 2024123108301204000_14.12.e091441.47 Zhang (2024123108301204000_14.12.e091441.14) 2008; 10 2024123108301204000_14.12.e091441.22 2024123108301204000_14.12.e091441.44 2024123108301204000_14.12.e091441.45 2024123108301204000_14.12.e091441.20 2024123108301204000_14.12.e091441.21 Chrostek (2024123108301204000_14.12.e091441.9) 2019; 9 Peng (2024123108301204000_14.12.e091441.27) 2015; 6 Israel (2024123108301204000_14.12.e091441.33) 2016; 13 Thompson (2024123108301204000_14.12.e091441.11) 2020; 19 Wang (2024123108301204000_14.12.e091441.12) 2021; 12 2024123108301204000_14.12.e091441.29 Hamelin (2024123108301204000_14.12.e091441.36) 2016; 139 Schulz (2024123108301204000_14.12.e091441.42) 2010; 340 2024123108301204000_14.12.e091441.5 Kabat (2024123108301204000_14.12.e091441.26) 2020; 9 2024123108301204000_14.12.e091441.4 2024123108301204000_14.12.e091441.30 2024123108301204000_14.12.e091441.3 2024123108301204000_14.12.e091441.2 Cheval (2024123108301204000_14.12.e091441.38) 2023; 101 2024123108301204000_14.12.e091441.8 2024123108301204000_14.12.e091441.6 2024123108301204000_14.12.e091441.15 2024123108301204000_14.12.e091441.37 2024123108301204000_14.12.e091441.16 2024123108301204000_14.12.e091441.35 2024123108301204000_14.12.e091441.1 Wang (2024123108301204000_14.12.e091441.17) 2013; 1532 2024123108301204000_14.12.e091441.34 2024123108301204000_14.12.e091441.31 2024123108301204000_14.12.e091441.32 Brazinova (2024123108301204000_14.12.e091441.46) 2021; 38 |
| References_xml | – volume: 70 start-page: 374 year: 2011 ident: R4 article-title: Inflammation after trauma: microglial activation and traumatic brain injury publication-title: Ann Neurol doi: 10.1002/ana.22455 – volume: 13 start-page: 171 year: 2017 ident: R5 article-title: The far-reaching scope of neuroinflammation after traumatic brain injury publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2017.13 – volume: 54 start-page: 1320 year: 2013 ident: R24 article-title: Influence of TSPO genotype on 11C-PBR28 standardized uptake values publication-title: J Nucl Med doi: 10.2967/jnumed.112.118885 – volume: 35 start-page: 1065 year: 2017 ident: R19 article-title: Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells publication-title: Stem Cells doi: 10.1002/stem.2538 – volume: 1532 start-page: 76 year: 2013 ident: R17 article-title: Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury publication-title: Brain Res doi: 10.1016/j.brainres.2013.08.001 – volume: 137 start-page: 731 year: 2019 ident: R29 article-title: The complexity of neuroinflammation consequent to traumatic brain injury: from research evidence to potential treatments publication-title: Acta Neuropathol doi: 10.1007/s00401-018-1944-6 – volume: 94 start-page: 366 year: 2023 ident: R37 article-title: Positron Emission Tomography with [18 F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression publication-title: Ann Neurol doi: 10.1002/ana.26657 – volume: 340 year: 2010 ident: R42 article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials publication-title: BMJ doi: 10.1136/bmj.c332 – volume: 66 start-page: 75 year: 2015 ident: R6 article-title: Epidemiology of mild traumatic brain injury and neurodegenerative disease publication-title: Mol Cell Neurosci doi: 10.1016/j.mcn.2015.03.001 – volume: 61 start-page: 10 year: 2013 ident: R31 article-title: Molecular imaging of microglia/macrophages in the brain publication-title: Glia doi: 10.1002/glia.22357 – volume: 113 start-page: 556 year: 2010 ident: R30 article-title: Prevalence and impact of diffuse axonal injury in patients with moderate and severe head injury: a cohort study of early magnetic resonance imaging findings and 1-year outcome publication-title: J Neurosurg doi: 10.3171/2009.9.JNS09626 – volume: 9 year: 2019 ident: R7 article-title: Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats publication-title: Sci Rep doi: 10.1038/s41598-019-49428-y – volume: 104 start-page: 272 year: 2006 ident: R25 article-title: Long-term recovery after bone marrow stromal cell treatment of traumatic brain injury in rats publication-title: J Neurosurg doi: 10.3171/jns.2006.104.2.272 – volume: 139 start-page: 1252 year: 2016 ident: R36 article-title: Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging publication-title: Brain (Bacau) doi: 10.1093/brain/aww017 – volume: 37 start-page: 171 year: 2018 ident: R23 article-title: Management of severe traumatic brain injury (first 24hours) publication-title: Anaesth Crit Care Pain Med doi: 10.1016/j.accpm.2017.12.001 – volume: 32 start-page: 5728 year: 2012 ident: R34 article-title: Imaging microglial/macrophage activation in 29 spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2900-11.2012 – volume: 26 year: 2022 ident: R43 article-title: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial publication-title: Crit Care doi: 10.1186/s13054-022-03930-4 – volume: 13 start-page: 140 year: 2016 ident: R33 article-title: Combined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice publication-title: J Neuroinflamm doi: 10.1186/s12974-016-0604-9 – volume: 9 start-page: 17 year: 2020 ident: R26 article-title: Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? publication-title: Stem Cells Transl Med doi: 10.1002/sctm.19-0202 – volume: 12 start-page: 545 year: 2021 ident: R12 article-title: The safety of MSC therapy over the past 15 years: a meta-analysis publication-title: Stem Cell Res Ther doi: 10.1186/s13287-021-02609-x – volume: 82 start-page: 29 year: 2021 ident: R32 article-title: Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2020.11.011 – volume: 6 start-page: 221 year: 2011 ident: R45 article-title: Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine publication-title: Curr Stem Cell Res Ther doi: 10.2174/157488811796575332 – volume: 30 start-page: 791 year: 2016 ident: R1 article-title: Pharmacologic Neuroprotection for Functional Outcomes After Traumatic Brain Injury: A Systematic Review of the Clinical Literature publication-title: CNS Drugs doi: 10.1007/s40263-016-0355-2 – volume: 158 start-page: 200 year: 2013 ident: R21 article-title: SPIRIT 2013 statement: defining standard protocol items for clinical trials publication-title: Ann Intern Med doi: 10.7326/0003-4819-158-3-201302050-00583 – volume: 19 year: 2020 ident: R11 article-title: Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis publication-title: E Clin Med doi: 10.1016/j.eclinm.2019.100249 – volume: 38 start-page: 333 year: 2018 ident: R41 article-title: Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies publication-title: J Cereb Blood Flow Metab doi: 10.1177/0271678X17692599 – volume: 6 year: 2021 ident: R10 article-title: Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury publication-title: NPJ Regen Med doi: 10.1038/s41536-021-00182-8 – volume: 101 start-page: e1893 year: 2023 ident: R38 article-title: [18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy publication-title: Neurology (ECronicon) doi: 10.1212/WNL.0000000000207811 – volume: 27 year: 2023 ident: R13 article-title: The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials publication-title: Crit Care doi: 10.1186/s13054-022-04287-4 – volume: 68 start-page: 588 year: 2011 ident: R15 article-title: Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children publication-title: Neurosurgery doi: 10.1227/NEU.0b013e318207734c – volume: 8 year: 2017 ident: R28 article-title: Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury publication-title: Front Neurol doi: 10.3389/fneur.2017.00028 – volume: 8 start-page: 144 year: 2013 ident: R44 article-title: Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications publication-title: Curr Stem Cell Res Ther doi: 10.2174/1574888x11308020005 – volume: 336 start-page: 309 year: 1997 ident: R47 article-title: Uniform Requirements for Manuscripts Submitted to Biomedical Journals publication-title: N Engl J Med doi: 10.1056/NEJM199701233360422 – volume: 9 year: 2019 ident: R9 article-title: Efficacy of Cell-Based Therapies for Traumatic Brain Injuries publication-title: Brain Sci doi: 10.3390/brainsci9100270 – volume: 10 start-page: 134 year: 2008 ident: R14 article-title: A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury publication-title: Cytotherapy doi: 10.1080/14653240701883061 – volume: 35 start-page: 157 year: 2015 ident: R40 article-title: Automated reference region extraction and population-based input function for brain [(11)C]TMSX PET image analyses publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2014.194 – volume: 16 start-page: 245 year: 2015 ident: R18 article-title: Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children* publication-title: Pediatr Crit Care Med doi: 10.1097/PCC.0000000000000324 – volume: 38 start-page: 1411 year: 2021 ident: R46 article-title: Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review publication-title: J Neurotrauma doi: 10.1089/neu.2015.4126 – volume: 6 year: 2015 ident: R27 article-title: Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury publication-title: Stem Cell Res Ther doi: 10.1186/s13287-015-0034-0 – volume: 16 start-page: 452 year: 2017 ident: R22 article-title: Severe traumatic brain injury: targeted management in the intensive care unit publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30118-7 – year: 2017 ident: R20 article-title: Safety of neural stem cell transplantation in patients with severe traumatic brain injury publication-title: Exp Ther Med doi: 10.3892/etm.2017.4423 – volume: 41 start-page: 1440 year: 2014 ident: R35 article-title: PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-014-2727-5 – volume: 36 start-page: 471 year: 2015 ident: R3 article-title: Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2015.04.003 – volume: 11 start-page: 176 year: 2013 ident: R16 article-title: Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture publication-title: Exp Clin Transplant doi: 10.6002/ect.2012.0053 – volume: 39 start-page: 311 year: 2016 ident: R2 article-title: Traumatic Axonal Injury: Mechanisms and Translational Opportunities publication-title: Trends Neurosci doi: 10.1016/j.tins.2016.03.002 – volume: 33 start-page: 1725 year: 2013 ident: R39 article-title: Reference region automatic extraction in dynamic [(11)C]PIB publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2013.133 – volume: 9 year: 2019 ident: 2024123108301204000_14.12.e091441.9 article-title: Efficacy of Cell-Based Therapies for Traumatic Brain Injuries publication-title: Brain Sci doi: 10.3390/brainsci9100270 – ident: 2024123108301204000_14.12.e091441.34 doi: 10.1523/JNEUROSCI.2900-11.2012 – ident: 2024123108301204000_14.12.e091441.32 doi: 10.1016/j.parkreldis.2020.11.011 – volume: 1532 start-page: 76 year: 2013 ident: 2024123108301204000_14.12.e091441.17 article-title: Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury publication-title: Brain Res doi: 10.1016/j.brainres.2013.08.001 – ident: 2024123108301204000_14.12.e091441.30 doi: 10.3171/2009.9.JNS09626 – volume: 19 year: 2020 ident: 2024123108301204000_14.12.e091441.11 article-title: Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis publication-title: E Clin Med – ident: 2024123108301204000_14.12.e091441.29 doi: 10.1007/s00401-018-1944-6 – volume: 26 year: 2022 ident: 2024123108301204000_14.12.e091441.43 article-title: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial publication-title: Crit Care doi: 10.1186/s13054-022-03930-4 – ident: 2024123108301204000_14.12.e091441.3 doi: 10.1016/j.tips.2015.04.003 – ident: 2024123108301204000_14.12.e091441.22 doi: 10.1016/S1474-4422(17)30118-7 – volume: 13 start-page: 140 year: 2016 ident: 2024123108301204000_14.12.e091441.33 article-title: Combined [(18)F]DPA-714 micro-positron emission tomography and autoradiography imaging of microglia activation after closed head injury in mice publication-title: J Neuroinflamm doi: 10.1186/s12974-016-0604-9 – ident: 2024123108301204000_14.12.e091441.39 doi: 10.1038/jcbfm.2013.133 – ident: 2024123108301204000_14.12.e091441.24 doi: 10.2967/jnumed.112.118885 – ident: 2024123108301204000_14.12.e091441.31 doi: 10.1002/glia.22357 – ident: 2024123108301204000_14.12.e091441.2 doi: 10.1016/j.tins.2016.03.002 – ident: 2024123108301204000_14.12.e091441.6 doi: 10.1016/j.mcn.2015.03.001 – volume: 340 year: 2010 ident: 2024123108301204000_14.12.e091441.42 article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials publication-title: BMJ doi: 10.1136/bmj.c332 – ident: 2024123108301204000_14.12.e091441.45 doi: 10.2174/157488811796575332 – volume: 27 year: 2023 ident: 2024123108301204000_14.12.e091441.13 article-title: The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials publication-title: Crit Care doi: 10.1186/s13054-022-04287-4 – ident: 2024123108301204000_14.12.e091441.35 doi: 10.1007/s00259-014-2727-5 – ident: 2024123108301204000_14.12.e091441.8 doi: 10.1016/B978-0-12-809880-6.00023-0 – ident: 2024123108301204000_14.12.e091441.16 doi: 10.6002/ect.2012.0053 – ident: 2024123108301204000_14.12.e091441.18 doi: 10.1097/PCC.0000000000000324 – volume: 35 start-page: 1065 year: 2017 ident: 2024123108301204000_14.12.e091441.19 article-title: Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells publication-title: Stem Cells doi: 10.1002/stem.2538 – ident: 2024123108301204000_14.12.e091441.4 doi: 10.1002/ana.22455 – volume: 139 start-page: 1252 year: 2016 ident: 2024123108301204000_14.12.e091441.36 article-title: Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging publication-title: Brain (Bacau) doi: 10.1093/brain/aww017 – volume: 9 year: 2019 ident: 2024123108301204000_14.12.e091441.7 article-title: Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats publication-title: Sci Rep doi: 10.1038/s41598-019-49428-y – volume: 10 start-page: 134 year: 2008 ident: 2024123108301204000_14.12.e091441.14 article-title: A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury publication-title: Cytotherapy doi: 10.1080/14653240701883061 – ident: 2024123108301204000_14.12.e091441.5 doi: 10.1038/nrneurol.2017.13 – volume: 6 year: 2021 ident: 2024123108301204000_14.12.e091441.10 article-title: Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury publication-title: NPJ Regen Med doi: 10.1038/s41536-021-00182-8 – ident: 2024123108301204000_14.12.e091441.20 doi: 10.3892/etm.2017.4423 – volume: 12 start-page: 545 year: 2021 ident: 2024123108301204000_14.12.e091441.12 article-title: The safety of MSC therapy over the past 15 years: a meta-analysis publication-title: Stem Cell Res Ther doi: 10.1186/s13287-021-02609-x – ident: 2024123108301204000_14.12.e091441.47 doi: 10.1056/NEJM199701233360422 – ident: 2024123108301204000_14.12.e091441.21 doi: 10.7326/0003-4819-158-3-201302050-00583 – ident: 2024123108301204000_14.12.e091441.40 doi: 10.1038/jcbfm.2014.194 – volume: 37 start-page: 171 year: 2018 ident: 2024123108301204000_14.12.e091441.23 article-title: Management of severe traumatic brain injury (first 24hours) publication-title: Anaesth Crit Care Pain Med doi: 10.1016/j.accpm.2017.12.001 – ident: 2024123108301204000_14.12.e091441.37 doi: 10.1002/ana.26657 – volume: 9 start-page: 17 year: 2020 ident: 2024123108301204000_14.12.e091441.26 article-title: Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? publication-title: Stem Cells Transl Med doi: 10.1002/sctm.19-0202 – ident: 2024123108301204000_14.12.e091441.1 doi: 10.1007/s40263-016-0355-2 – volume: 101 start-page: e1893 year: 2023 ident: 2024123108301204000_14.12.e091441.38 article-title: [18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy publication-title: Neurology (ECronicon) – ident: 2024123108301204000_14.12.e091441.25 doi: 10.3171/jns.2006.104.2.272 – ident: 2024123108301204000_14.12.e091441.44 doi: 10.2174/1574888X11308020005 – volume: 38 start-page: 1411 year: 2021 ident: 2024123108301204000_14.12.e091441.46 article-title: Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review publication-title: J Neurotrauma doi: 10.1089/neu.2015.4126 – ident: 2024123108301204000_14.12.e091441.15 doi: 10.1227/NEU.0b013e318207734c – volume: 8 year: 2017 ident: 2024123108301204000_14.12.e091441.28 article-title: Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury publication-title: Front Neurol doi: 10.3389/fneur.2017.00028 – ident: 2024123108301204000_14.12.e091441.41 doi: 10.1177/0271678x17692599 – volume: 6 year: 2015 ident: 2024123108301204000_14.12.e091441.27 article-title: Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury publication-title: Stem Cell Res Ther doi: 10.1186/s13287-015-0034-0 |
| SSID | ssj0000459552 |
| Score | 2.378347 |
| Snippet | IntroductionTraumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has... Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has been shown to... Introduction Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. Treatments for TBI patients are limited and none has... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | e091441 |
| SubjectTerms | Adolescent Adult Adult intensive & critical care Anesthesia Angiogenesis Biomarkers Bone marrow Brain damage Brain Injuries Brain Injuries, Traumatic - therapy Clinical Trial Clinical Trials, Phase III as Topic Cytokines Double-Blind Method Female Humans Immunomodulation Intensive Care Male Mesenchymal Stem Cell Transplantation - methods Mesenchymal Stem Cells Middle Aged Multicenter Studies as Topic Neurogenesis Neuroinflammatory Diseases - etiology Neuroinflammatory Diseases - therapy Neuroradiology NUCLEAR MEDICINE Patients Pharmacokinetics Prospective Studies Protocol Randomized Controlled Trials as Topic Tomography Toxicity Traumatic brain injury Umbilical cord Umbilical Cord - cytology Wharton Jelly - cytology Young Adult |
| SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9NAEF1KkapeEFA-AgUNEoci4Sb2rh0vt1C1qqqGA0pEOVm73nGTCtuoSZB642_w9_glzKztQBBCnBx515vR-q3njT37RohX5IGUUzYO0BQuUBGGAbHWNCjC3BpEZYc-2338PjmdqrOL-GJLRN1eGFtecdmoQzo2OxpYo6la9kPVD6M-kncj_33Ir6ZvizusxcVpfPrTZP1ehSiKjn2hnWigVEBsPW7FhkKZdMMTNiIVNIPtih3yyRzmhORfqMOGh_JC_n9jn38mUf7mlU7uibstnYRRc__viy2sHoidcfvBfO_WXqNOvIC6gDmP0GWegtlQzeX2kjci5bObkgak8zUf-b3-AhzB9Cs64L0o8HFGaKurH9--L-CMmm_4WqKRsCo50TbnqyiiBRq0kYme5zDnXSh1Wbu2WBiYyoGX0iSAEybL9iwXLAcyaeWFZMFy_Qqy-4puPBxMPoym49HR8fn567fgZXGBVSZqgjIQ9QYDPjvSzxQC-WBXE4jJ7DYd_zP99EVKHorpyfHk6DRoC0EEVunBksLbaOisMZoJYoQSiaOkSYoqNyZyOkaZGKkSelZRuIpYDF08dEmsOeeUd13LR2K7qit8IiCVaYqFdZFFpZyzOiVCQ6wudyHqXKY9cUAQyNqFvMh8jCSTrAVOxsDJGuD0xJsOJ9mXRhrk393fMZbWXVnX25-ory-z9jGRWYycJLMNRXEKc21zaQcFsawhhloVNMh-h8RfNsqQv0XTvyQ98XLdTDPMGDEV1qumTxzxZ7WeeNwAd21JB_-eSDcgvWHqZks1n3kp8pACWh1L9fT_p-2Z2PWrz4tl7ovt5fUKnxOxW9oXfiX_BBoYTxo priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9NAEF2gB8QFAeXDpaBB4lAkrMbeXX9wC1Wrqmo4oEb0Zu16x0oqbKMmQeqNv8Hf45cws3ZCjBBcOCXaXW8mm2fPm-zsGyFekwdSTlkdoqlcqGKMQmKtWVhFpTWIyqY-233yITmdqrNLfblV6otzwjp54G7hDi3GTo7ykSFeq7DMbSntqCK_kyLF35UPfKh7K5jyz2Clc63jXmYoksmhra-4HhWhIlYhOUnFNeDvUOvAIXnd_j-Rzd9zJrec0MkDcb9njzDurH4obmPzSNyd9Pvju7d2OzHiBbQVzHmGdaIpmIFILvfXfO6onN3UNCG1t_zKf-MvwBEqv6IDPnoCn2a0Rm3z49v3BZxR9w1fS6wRVjXn1ZZ8FQWwQJN2qtDzEuZ86KStW9fXBgPTOPDKmYRngmDdt3J9ciCTVl43FiyXqyC7r-h3hoOLj-PpZHx0fH7-5h14FVxgUYmWkAvEtMGAT4b0K4VALte1hFkyu8--_0xvfU2Sx2J6cnxxdBr2dR9Cq_LRkqLZOHXWmJz5YIwSiZJkSYaqNCZ2uUaZGKkSejRRdIpYpU6nLtE5p5jyIWv5ROw0bYPPBGQyy7CyLraolHM2z4i_EIkrXYR5KbNAHBAEiv6-XRQ-JJJJ0aOlYLQUHVoC8XaNk-JLpwTy9-HvGUuboSzj7RsI3EUP7uJf4A7E_hqJv2yUEW8906ckgXi16aYVZoyYBttVN0bHvIsWiKcdcDeWEAPloJ4mzwaQHpg67GnmM688HlH8mmup9v7Hl3su7vmb0atm7oud5fUKXxDDW9qX_mb-Cas7Vks priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwEDW0SIgLAsrHQkGDxKFIRN0kzhcXtFStqqrLAXXF3iI7nrBbkbg0u0i98Tf4e_wSZhzvlkWop13ZjjVKnu039viNEG9oBZJG6iRAVZtARhgGxFrzoA4rrRClzly0-_hTejyRJ9Nk6jfcOh9WuZoT3URtbMV75PtxyAdutLqlHy6-B5w1ik9XfQqNLXEnJCbCqRuyabbeYyG6UiRJ5MWGwjjd1805Z6UibEQyoM4kZ4LfotKNZcmp9_-Pcv4bOfnXUnT0QNz3HBJG_Ud_KG5j-0jcHftT8p1bO70kcQe2hjn3sAo3BbUhlcv1Dd8-qmZXDXVI5ZZ_eTO_A0PY_IEG-AIKfJkRxGz7--evDk6o-oqfJe4Iy4ajayt-itxYoE57beh5BXO-emIba3yGMFCtAaefSagmIDa-lLOUA5m0dOqxoDlpBdl9Tl8b9s4-jybj0cHh6enb9-C0cIGlJSzhF4hvgwIXEuneFAItvMYScslsH4P_jf66zCSPxeTo8OzgOPDZHwIti-GCfNooM1qpgllhhDESMcnTHGWlVGSKBONUxTKlCYp8VMQ6M0lm0qTgQFO-ah0_EdutbfGZgDzOc6y1iTRKaYwucmIxROUqE2JRxflA7BEESj96u9I5RnFaerSUjJayR8tAvFvhpLzo9UBubv6RsbRuymLersBefi393FBqjAwhe6jIdZNYFbqK9bAmapVhWMiaOtldIfHaxuvxMBCv19X0hhkjqkW77NskEZ-lDcTTHrhrS4iHsmtPnecbkN4wdbOmnc-c_nhIXmyRxPL5zXa9EPfcMHOqmLtie3G5xJfE4Bb6lRumfwBwo02p priority: 102 providerName: ProQuest |
| Title | Effects of intravascular administration of mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord on systemic immunomodulation and neuroinflammation after traumatic brain injury (TRAUMACELL): study protocol for a multicentre randomised controlled trial |
| URI | https://bmjopen.bmj.com/content/14/12/e091441.full https://www.ncbi.nlm.nih.gov/pubmed/39740941 https://www.proquest.com/docview/3150330916 https://www.proquest.com/docview/3150523222 https://pubmed.ncbi.nlm.nih.gov/PMC11749534 https://doaj.org/article/be2d3090a5854ec9bc3b0f2417e194f1 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1rb9MwFDVjkxBfEONZGJWRkBgSgSZxXkgIdVXHNK0TmlYon6I4dminJYE-EP33nOu4haKB-JJEduJcOSfxufH1uYw9wwgklJCBo7NCOcLTrgPWGjuFm8tMayEjE-0-OA2PhuJ4FIy22Corqu3A2ZWuHeWTGk4vX_34tnyHF_6tzUjyWpYXVIUH7gkH45-ghew7ZsKIYvks3zefZhEkgcnC43WEcEDlA6tE9Jd2MOKgdGPMMtL-V_HRP8MqfxunDm-zW5Zg8m6DiF22pas77MbATqHfvbbb6BXPeF3wCbWwikXl2YaOLtWXtDQpHy9LNIjymvb0p3_GFYD7XStOq1P4pzHwV1fPZ_wYlUu6ErSSL0oKvM3pGni4HE02stGTnE9oVUpd1somD-NZpbiR1sQjAEZLW0oJzDkMWhhhWS4pnwWsvgAQ-P75WXc46Pb6Jycv3nAjk8tJdaIGtDmoOM-4iZY0_aQ5xmRVA9Qw2obnX-LQJC25x4aH_fPekWMTQzhSJJ053F0vUjLLEiKMnvY1OEscxlrkWeapJNB-mPkixLcL7qvWRaSCSIVBQjGotArbv8-2q7rSDxmP_TjWhVSe1EIoJZMYBAcsL1euTnI_brF9ACBd4TI1PpMfphYrKWElbbDSYi9XKEm_NlIh_z79gJC0PpV0vk1BPf2S2s9GKrWnfJidwasTOk9k7stOAWhH2k1EgUb2Vjj8ZaPv0tw07hK22NN1NXqYEJJVul405wQeTbO12IMGtmtLQFHJ60fj8QagN0zdrKkmYyNN7sLBTQJfPPqPGz9mN82bZlQz99j2fLrQT8Dw5rLNrkejCNvk83mb7XR7g8FH7A_6px_O2uavCbbvR27bvN0_AR3nW18 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwEDdbJwEvCBh_CgMOCaQhEa1JnDRBmlA3OnVbW6Fp1fYW7NihnUgy1hbUN74GX4YPwyfhznE7itDe9tTKTqxL8jv7zr77HWOvcAXiisvA0SJTDve066DVGjmZm0qhNZdNE-3e64edAT84DU5X2K95LgyFVc7nRDNRqzKlPfIt36UDN1zdwvfnXx2qGkWnq_MSGsKWVlDbhmLMJnYc6tl3dOHG2_sf8Hu_9ry99vFux7FVBhzJ48YEfSevqaQQMVkfnvY1LoBRGGmeCuGpONB-KHweoiKgL6R11lRBU4VBTAGNlNLr47irbI3TBkqNre20-x-PFrs8aDDFQeBZuiPXD7dkfkZ1sRCdHnfwcTjVol_F1qWF0dQP-J_R-2_s5l-L4d5ddsdasdCqYHePrejiPrvZs-f06zfWK1LkMZQZjGiEecAriCWyXurPKf8pHc5yHBDbS_ql44QxKNSOb1oBpcDAyRBBXha_f_wcwwF2z-hetF5hmlN8b0p34VcAHLRipx6lMKLklzIvla1RBqJQYBg8Ua9QFXLbSnXSAUWaGv5akFQ2A-U-Q7zB5vFRa9Br7ba73TfvwLDxApFblKhBgBY_CDBBmeZNacClX5WoOyi2zQL4gn9NbZQHbHAtyHjIakVZ6McMIj-KdCaVJzXnSsk4QjsKjclUuTpO_ajONhECiZ0_xolxzfwwsWhJCC1JhZY6ezvHSXJeMZJcffkOYWlxKdGJm4by4nNiZ6dEak-hbjUEOo9cp7FMfdnI0LhrajfmGQ6yMUfipYyXGllnLxfd-IYJI6LQ5bS6JvDoNK_OHlXAXUiCljBtLuDg0RKkl0Rd7ilGQ8OA7qIfHQc-f3K1XC_Yrc5xr5t09_uHT9lto3KGo3OD1SYXU_0M7cmJfG6VFtin654n_gChd46r |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFDa7SBMvCBiXwoCDBNKQiNokTpogTajbOu3SVtO0ansLduzQTiQZawvqG3-Dv8TP4JdwjuN2FKG97amVnVgnyXfs79jnwtgbXIG44jJwtMiUwz3tOshaIydzUym05rJpvN27vXC_zw_Pg_Ml9msWC0NulbM50UzUqkxpj7zuu3TghqtbWM-sW8Tx7t7Hy68OVZCik9ZZOQ1hyyyoLZNuzAZ5HOnpdzTnRlsHu_jt33reXvt0Z9-xFQccyePGGO0or6mkEDExEU_7GhfDKIw0T4XwVBxoPxQ-D1Ep0C7SOmuqoKnCICbnRgrv9XHcZbbaxFUfDcHV7Xbv-GS-44PkKQ4Cz6Y-cv2wLvMLqpGFSPW4g4_GqS79MrYuLJKmlsD_CPC_fpx_LYx799k9y2ihVUHwAVvSxUO21rVn9ut31qsEySMoMxjSCDPnVxALiXupP6dYqHQwzXFAbC_pl44WRqBQU75pBRQOA2cDBHxZ_P7xcwSH2D2le5HJwiQnX9-U7sKvADholal6mMKQAmHKvFS2XhmIQoHJ5ok6hmqR21aqmQ4o0sTksgVJJTRQ7gvEHmyenrT63dZOu9N59wFMZl6gRBclahMg-wcBxkHTvCkNSANUiXqEYtuIgC_419RJecT6t4KMx2ylKAv9lEHkR5HOpPKk5lwpGUfIqZBYpsrVcepHNbaJEEjsXDJKjJnmh4lFS0JoSSq01Nj7GU6Syyo7yc2XbxOW5pdSanHTUF59TuxMlUjtKdSzhkBDkus0lqkvGxkSvaZ2Y57hIBszJF7LeK2dNfZ63o1vmDAiCl1OqmsCj072auxJBdy5JMiKaaMBB48WIL0g6mJPMRyYbOgu2tRx4PNnN8v1iq3hfJF0DnpHz9ldo3EmXecGWxlfTfQLpJZj-dLqLLBPtz1N_AFHjJLv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+intravascular+administration+of+mesenchymal+stromal+cells+derived+from+Wharton%27s+Jelly+of+the+umbilical+cord+on+systemic+immunomodulation+and+neuroinflammation+after+traumatic+brain+injury+%28TRAUMACELL%29%3A+study+protocol+for+a+multicentre+randomised+controlled+trial&rft.jtitle=BMJ+open&rft.au=Sigaut%2C+St%C3%A9phanie&rft.au=Tardivon%2C+Coralie&rft.au=Jacquens%2C+Alice&rft.au=Bottlaender%2C+Michel&rft.date=2024-12-31&rft.issn=2044-6055&rft.eissn=2044-6055&rft.volume=14&rft.issue=12&rft.spage=e091441&rft_id=info:doi/10.1136%2Fbmjopen-2024-091441&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-6055&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-6055&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-6055&client=summon |